Fig. 2

Safety profile and clinicopathologic parameters analysis of the study. a Representative magnetic resonance (MR) or computed tomography (CT) images of the complete response (CR) cases in our cohorts. Lesions are marked with horizontal lines indicating their longest target diameters. CT and MR images of CR patient 1023 with PDAC (the top row: metastatic lesion 1 in the peritoneum; the middle row: metastatic lesion 2 in the peritoneum; the bottom row: metastatic lesion in the lung). CT images of CR patient 2013 with BTC (metastatic lesion in the peritoneum). Detailed patient background information can be found in Supplementary Data S1. b Overview of treatment-related adverse events (TRAEs) by grade in organ systems with grade 3–4 events. c Forest plot of hazard ratios (HR) and 95% confidence intervals (CI) for overall survival (OS) based on various clinicopathological factors in the overall population. Factors favoring OS are shown on the right side of the plot, while factors against OS are shown on the left side. The category of local treatment includes ablation, radiation and intra-arterial therapy. **, P < 0.01; SOD, sum of diameter; NLR, neutrophil-to-lymphocyte ratio. d Top: comparison of peripheral blood mononuclear cell (PBMC) cluster proportions before treatment (pre-treatment) and 6 weeks post-treatment. N = 37 evaluable patients. Statistical significance was determined by Bonferroni’s multiple comparison test. *P < 0.05; **P < 0.01; ***P < 0.001. Bottom: comparison of CD4⁺CD25⁺CD127^low, CD3^-CD16⁺CD56⁺, CD3⁺HLA-DR⁺ and CD3⁺HLA-DR^- cell cluster proportion pre- and post-treatment split by clinical response. N = 8 clinical responders (R), N = 29 clinical non-responders (NR). Statistical significance was determined using the Mann-Whitney U test